Where Should We Be Looking for the Future of IOP Lowering Drugs? Commentary on "New Therapeutic Targets for Intraocular Pressure Lowering"

Journal of Clinical & Experimental Ophthalmology
doi 10.4172/2155-9570.1000525
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group

Related search

Should Women Be Offered Cholesterol Lowering Drugs to Prevent Cardiovascular Disease? Yes

BMJ
2007English

Effectiveness of Intraocular Pressure–Lowering Medication Determined by Washout

JAMA Ophthalmology
Ophthalmology
2014English

Autotaxin-Lysophosphatidic Acid Axis Is a Novel Molecular Target for Lowering Intraocular Pressure

PLoS ONE
Multidisciplinary
2012English

Blood Pressure Lowering for Cardiovascular Disease

The Lancet
Medicine
2016English

Governance Indicators: Where Are We, Where Should We Be Going?

World Bank Research Observer
DevelopmentEconomicsEconometrics
2007English

Lowering of Blood Pressure for Recurrent Stroke Prevention

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
2014English

Tonometry and Intraocular Pressure – Where Are We Now?

European Ophthalmic Review
2016English

Effects of Currently Prescribed LDL-C-lowering Drugs on PCSK9 and Implications for the Next Generation of LDL-C-lowering Agents

Lipids in Health and Disease
BiochemistryEndocrinologyClinical BiochemistryMetabolismDiabetes
2011English

Comparison of Intraocular Pressure-Lowering Effects of Ripasudil Hydrochloride Hydrate for Inflammatory and Corticosteroid-Induced Ocular Hypertension

PLoS ONE
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy